Examining the Data From Key Clinical Trials, and Practical Strategies

No patients in the transperineal cohort experienced an infection, compared with 1.6% of patients in the transrectal cohort.

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

Patients with at least 1 NE-positive marker were shown to have a worsened rPFS and OS.

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

New data from ESMO 2024 support an initial dose of Radium223 prior to chemotherapy among patients with mCRPC.

New findings from the open-label SPLASH trial show patients with mCRPC achieved improved progression-free survival as well as response rates and antigen-specific reductions.